Malaria chemotherapy: Recent advances in drug development

Recent Patents on Anti-Infective Drug Discovery

Volumn 5, Issue 3, 2010, Pages 195-225

  Gemma, Sandra ^a   Travagli, Valter ^a   Savini, Luisa ^a   Novellino, Ettore ^a,b   Campiani, Giuseppe ^a   Butini, Stefania ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Drug delivery; Drug resistant malaria; Heme detoxification; Protease inhibitors

Indexed keywords

1,2,6,7 TERTRAOXAPISRO[7.11]NONADECANE; 4 AMINOQUINOLINE; 4 AMINOQUINOLINE DERIVATIVE; AMDOXOVIR; AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ATOVAQUONE; CHLOROQUINE; CHLORPHENIRAMINE; CLOTRIMAZOLE; CTC 96; DESIPRAMINE; FALCILYSIN; FALCIPAIN; FALCIPAIN 2; FEBRIFUGINE; GELDANAMYCIN; HALOFANTRINE; HETEROCYCLIC COMPOUND; HYDROXYCHLOROQUINE; MEFLOQUINE; METALLOPROTEINASE; NITRILE; ORPHENADRINE; PHYTOMENADIONE DERIVATIVE; PLASMEPSIN INHIBITOR; PRIMAQUINE; PYRIMETHAMINE; QUININE; SULFADOXINE; TDR 17516; TDR 22093; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CELL DIVISION; CHEMOSENSITIZATION; DETOXIFICATION; DNA REPLICATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG SYNTHESIS; GENE SEQUENCE; HUMAN; MALARIA; MALARIA CONTROL; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; HUMANS; MALARIA; PATENTS AS TOPIC; PLASMODIUM FALCIPARUM;

EID: 78650003029     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489110793348776     Document Type: Article

References (282)

1. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: Past, present, and future. Lancet Infect Dis 2004; 4: 327-36.
2. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis 2009; 3: e440.
3. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med 2009; 361: 540-1.
4. Schlitzer M. Antimalarial drugs - what is in use and what is in the pipeline. Arch Pharm (Weinheim) 2008; 341: 149-63.
5. Na-Bangchang K, Karbwang J. Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. Fundam Clin Pharmacol 2009; 23: 387-409.
6. Kremsner PG, Krishna S. Antimalarial combinations. Lancet 2004; 364: 285-94.
7. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 2009; 7: 999-1013.
8. Eastman RT, Fidock DA. Artemisinin-based combination therapies: A vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009; 7: 864-74.
9. Ogbonna A, Uneke CJ. Artemisinin-based combination therapy for uncomplicated malaria in sub-Saharan Africa: The efficacy, safety, resistance and policy implementation since Abuja 2000. Trans R Soc Trop Med Hyg 2008; 102: 621-7.
10. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: Meta-analysis. Lancet 2004; 363: 9-17.
11. Khan SM, Waters AP. Malaria parasite transmission stages: An update. Trends Parasitol 2004; 20: 575-80.
12. MJ. Malarial proteases and host cell egress: An 'emerging' cascade. Cell Microbiol 2008; 10: 1925-34.
13. Lanteri CA, Johnson JD, Waters NC. Recent advances in malaria drug discovery. Recent Pat Antiinfect Drug Discov 2007; 2: 95-114.
14. Russo I, Babbitt S, Muralidharan V, Butler T, Oksman A, Goldberg DE. Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte. Nature 2010; 463: 632-6.
15. Klemba M, Goldberg DE. Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparum. Mol Biochem Parasitol 2005; 143: 183-91.
16. Ball EG, Mc KR, Anfinsen CB, Cruz WO, Geiman QM. Studies on malarial parasites; chemical and metabolic changes during growth and multiplication in vivo and in vitro. J Biol Chem 1948; 175: 547-71.
17. Lew VL, Tiffert T, Ginsburg H. Excess hemoglobin digestion and the osmotic stability of Plasmodium falciparum-infected red blood cells. Blood 2003; 101: 4189-94.
18. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci USA 2002; 99: 990-5.
19. Francis SE, Sullivan DJ, Jr. Goldberg DE. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol 1997; 51: 97-123.
20. Goldberg DE, Slater AF, Beavis R, Chait B, Cerami A, Henderson GB. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: A catabolic pathway initiated by a specific aspartic protease. J Exp Med 1991; 173: 961-9.
21. Gluzman IY, Francis SE, Oksman A, Smith CE, Duffin KL, Goldberg DE. Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J Clin Invest 1994; 93: 1602-8.
22. Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci 2004; 74: 1957-72.
23. Homewood CA, Moore GA, Wwarhurst DC, Atkinson EM. Purification and some properties of malarial pigment. Ann Trop Med Parasitol 1975; 69: 283-7.
24. Slater AF, Swiggard WJ, Orton BR, Flitter WD, Goldberg DE, Cerami A, et al. An iron-carboxylate bond links the heme units of malaria pigment. Proc Natl Acad Sci USA 1991; 88: 325-9.
25. Pagola S, Stephens PW, Bohle DS, Kosar AD, Madsen SK. The structure of malaria pigment beta-haematin. Nature 2000; 404: 307-10.
26. Ginsburg H, Famin O, Zhang J, Krugliak M. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem Pharmacol 1998; 56: 1305-13.
27. Famin O, Krugliak M, Ginsburg H. Kinetics of inhibition of glutathione-mediated degradation of ferriprotoporphyrin IX by antimalarial drugs. Biochem Pharmacol 1999; 58: 59-68.
28. Becker K, Tilley L, Vennerstrom JL, Roberts D, Rogerson S. Ginsburg H. Oxidative stress in malaria parasite-infected erythrocytes: Host-parasite interactions. Int J Parasitol 2004; 34: 163-89.
29. Muller S. Redox and antioxidant systems of the malaria parasite Plasmodium falciparum. Mol Microbiol 2004; 53: 1291-305.
30. Payne D. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today 1988; 4: 112-5.
31. Ursos LM. Roepe PD. Chloroquine resistance in the malarial parasite, Plasmodium falciparum. Med Res Rev 2002; 22: 465-91.
32. Gemma S, Kukreja G, Fattorusso C, Persico M, Romano MP, Altarelli M, et al. Synthesis of N1-arylidene-N2-quinolyl- and N2- acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains. Bioorg Med Chem Lett 2006; 16: 5384-8.
33. Campiani, G., Fattorusso, C., Kukreja, G., Joshi, B.P., Fattorusso, E., De Angelis, M. Quinolin-4-ylhydrazine derivatives as antimalarial agent. WO2007104695 (2007).
34. Fattorusso C, Campiani G, Kukreja G, Persico M, Butini S, Romano MP, et al. Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents. J Med Chem 2008; 51: 1333-43.
35. Higuchi, T., Omiya, H., Umezawa, N., Kim, H.-S., Wataya, Y. Compound with antimalarial activity and antimalarial drug containing the same as active ingredient. WO2007097450 (2007), EP2006287 (2008), US20090275612 (2009).
36. Campiani, G., Gemma, S., Fattorusso, C., Kukreja, G., Joshi, B.P., Taglialatela, S.O. Antimalarial agents having polyaromatic structure. WO2007104696 (2007).
37. Gemma S, Campiani G, Butini S, Kukreja G, Coccone SS, Joshi BP, et al. Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: Design, synthesis, and biological and structure-activity relationship studies. J Med Chem 2008; 51: 1278-94.
38. Gemma S, Campiani G, Butini S, Kukreja G, Joshi BP, Persico M, et al. Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: Exploring an innovative pharmacophore. J Med Chem 2007; 50: 595-8.
39. Tiffert T, Ginsburg H, Krugliak M, Elford BC, Lew VL. Potent antimalarial activity of clotrimazole in in vitro cultures of Plasmodium falciparum. Proc Natl Acad Sci USA 2000; 97: 331-6.
40. Saliba KJ, Kirk K. Clotrimazole inhibits the growth of Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 1998; 92: 666-7.
41. Gemma S, Campiani G, Butini S, Joshi BP, Kukreja G, Coccone SS, et al. Combining 4-aminoquinoline - and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials. J Med Chem 2009; 52: 502-13.
42. Campiani, G., Gemma, S., Fattorusso, C., Kukreja, G., Joshi, B.P., Butini, S., Persico, M., Coccone, S.S., Bernetti, M. Novel 4-aminoquinoline derivatives useful as anti-malaria drugs. WO2008101891 (2008).
43. Sparatore, F. New anti-malaria derivatives of 4-aminoquinoline. WO2007045987 (2007).
44. F. 4-Aminoquinoline derivatives as antimalarials. US20080262031 (2008).
45. Wolf, C., Roepe, P.D., De Dios, A.C. Antimalarial quinolines and methods of use thereof. WO2009148659 (2009).
46. O'Neill PM, Ward SA, Berry NG, Jeyadevan JP, Biagini GA, Asadollaly E, et al. A medicinal chemistry perspective on 4- aminoquinoline antimalarial drugs. Curr Top Med Chem 2006; 6: 479-507.
47. Koepfli JB, Mead JF, Brockman JA. An Alkaloid with High Antimalarial Activity from Dichroa febrifuga. J Am Chem Soc 1947; 69: 1837.
48. Takeuchi Y, Koike M, Azuma K, Nishioka H, Abe H, Kim HS, et al. Synthesis and antimalarial activity of febrifugine derivatives. Chem Pharm Bull (Tokyo) 2001; 49: 721-5.
49. Takaya Y, Tasaka H, Chiba T, Uwai K, Tanitsu M, Kim HS, et al. New type of febrifugine analogues, bearing a quinolizidine moiety, show potent antimalarial activity against Plasmodium malaria parasite. J Med Chem 1999; 42: 3163-6.
50. Zhu, S. Pyridopyrimidinone compounds with antimalarial activity. US20080188498 (2008).
51. Dow, G.S., Smith, K., Heady, T.N. Quinoline methanol compounds for the treatment and prevention of parasitic infections. WO2008060269 (2008).
52. Dow GS, Heady TN, Bhattacharjee AK, Caridha D, Gerena L, Gettayacamin M, et al. Utility of alkylaminoquinolinyl methanols as new antimalarial drugs. Antimicrob Agents Chemother 2006; 50: 4132-43.
53. Puli, N., Banda, G., Uppalanchi, S., Mettu, R., Kumar, S.B., Chilukuri, R., Rao, V.J., Rao Janaswamy, M. An antimalarial Baylis-Hillman adducts and a process for the preparation thereof. WO2007032016 (2007).
54. Gershon, D. Method for the inhibition of Plasmodium in a plasmodium-infected patient. WO2008041989 (2008)
55. Egan TJ. Kaschula CH. Strategies to reverse drug resistance in malaria. Curr Opin Infect Dis 2007; 20: 598-604.
56. Henry M, Alibert S, Orlandi-Pradines E, Bogreau H, Fusai T, Rogier C, et al. Chloroquine resistance reversal agents as promising antimalarial drugs. Curr Drug Targets 2006; 7: 935-48.
57. Lee CH. Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 2010; 596: 325-40.
58. van Schalkwyk DA, Walden JC, Smith PJ. Reversal of chloroquine resistance in Plasmodium falciparum using combinations of chemosensitizers. Antimicrob Agents Chemother 2001; 45: 3171-4.
59. Smilkstein, M.J. Drug composition and method for treating malaria and malignancy. US20080108655 (2008).
60. Stella, L., Cisse, S. Use of voacamine and related compounds in the treatment of malaria. WO2007014450 (2007).
61. Kelly JX, Smilkstein MJ, Brun R, Wittlin S, Cooper RA, Lane KD, et al. Discovery of dual function acridones as a new antimalarial chemotype. Nature 2009; 459: 270-3.
62. Riscoe, M.K., Winter, R., Kelly, X.J., Hinrichs, D.J., Smilkstein, M.J. Acridone compounds. WO2008064011 (2008).
63. Klayman DL. Qinghaosu (artemisinin): An antimalarial drug from China. Science 1985; 228: 1049-55.
64. Samarasekera U. Countries race to contain resistance to key antimalarial. Lancet 2009; 374: 277-80.
65. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med 2009; 361: 540-1.
66. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, et al. Artemisinin resistance: Current status and scenarios for containment. Nat Rev Microbiol 2010; 8: 272-80.
67. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: An open randomized, non-inferiority, trial. Malar J 2010; 9: 105.
68. Katrak S, Gasasira A, Arinaitwe E, Kakuru A, Wanzira H, Bigira V, et al. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J 2009; 8: 272.
69. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: Meta-analysis. Lancet 2004; 363: 9-17.
70. Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J 2009; 8: 125.
71. Fraisse, L., Vial, H., Wein, S.A. Combination of a bisthiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria. WO2009115666 (2009).
72. Godha, P., Bansal, Y.K., Sengupta, S., Singhm, N. Antimalarial combination and methods of formulation. WO2007043061 (2007).
73. Gong, Q., Yan, X., Zheng, Q., Yu, Z. Compound antimalarial three-layered tablets containing artemisinin or its derivatives and its preparing method. CN100998569 (2007).
74. Kong, L., Wei, J. Preparation method for compound artemether dripping pill for treating malaria. CN101317839 (2008).
75. Liu, X., Yang, H., Yan, X., Zheng, Q., Gong, Q. Malaria treating medicine. CN1985843 (2007).
76. Lulla, A., Malhotra, G. Antimalarial composition. WO2007017646 (2007).
77. Padmanaban, G., Rangarajan, P.N., Nandakumar, D.N., Viswanathan, A.N. Antimalarial drug containing synergistic combination of curcumin and artemisinin. US2007105945 (2007).
78. Pareek, A. Synergistic antimalarial pharmaceutical composition. WO2010004573 (2010).
79. Platteeuw, J., Jansen, F.H. Pharmaceutical composition suitable for the treatment of malaria within one day. WO2007028413 (2007).
80. Shingatgeri, V.M., Udupa, V. Antimalarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative. US20090306091 (2009).
81. Touze, J.E. Combination of two molecules i.e. chloroquine and doxycycline, having antimalarial activity individually, for application to the malaria chemoprophylaxis. FR2891744 (2007).
82. Yan, X., Gong, Q., Pang, L., Ling, G., Pan, M., Zheng, Q. Compound preparation of antimalarial and its preparing method. CN100998571 (2007).
83. Coghi P, Basilico N, Taramelli D, Chan WC, Haynes RK, Monti D. Interaction of artemisinins with oxyhemoglobin Hb-FeII, Hb- FeII, carboxyHb-FeII, heme-FeII, and carboxyheme FeII: Significance for mode of action and implications for therapy of cerebral malaria. Chem Med Chem 2009; 4: 2045-53.
84. Haynes RK, Chan WC, Lung CM, Uhlemann AC, Eckstein U, Taramelli D, et al. The Fe2+-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: The unlikelihood of C-centered radicals as bioactive intermediates. Chem Med Chem 2007; 2: 1480-97.
85. CW. Why artemisinin and certain synthetic peroxides are potent antimalarials. Implications for the mode of action. Curr Med Chem 2001; 8: 1803-26.
86. Cumming JN, Ploypradith P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: Mechanism(s) of action. Adv Pharmacol 1997; 37: 253-97.
87. Wu Y. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Acc Chem Res 2002; 35: 255-9.
88. Robert A, Cazelles J, Meunier B. Characterization of the alkylation product of heme by the antimalarial drug artemisinin. We are grateful to the CNRS for financial support, and to the French Ministery of Education for a PhD grant to J.C. Dr. Yannick Coppel (LCC-CNRS) is gratefully acknowledged for discussions on NMR data. Angew Chem Int Ed Engl 2001; 40: 1954-7.
89. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424: 957-61.
90. Cardi D, Pozza A, Arnou B, Marchal E, Clausen JD, Andersen JP, et al. Purified E255L mutant SERCA1a and purified PFATP6 are sensitive to SERCA-type inhibitors but insensitive to artemisinins. J Bio Chem 2010 (in press).
91. O'Neill PM. Posner GH. A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 2004; 47: 2945-64.
92. Haynes RK, Fugmann B, Stetter J, Rieckmann K, Heilmann HD, Chan HW, et al. Artemisone--a highly active antimalarial drug of the artemisinin class. Angew Chem Int Ed Engl 2006; 45: 2082-8.
93. Haynes, R.K., Lam, W.W.-L., Chan, H.-W., Tsang, H.-W., Cheung, M.-K., Greif, G., Schmuck, G., Voerste, A. Antiparasitic artemisinin derivatives (endoperoxides). US20070191354 (2007), US7452915 (2008).
94. Thanh Nga TT, Menage C, Begue JP, Bonnet-Delpon D, Gantier JC, Pradines B, et al. Synthesis and antimalarial activities of fluoroalkyl derivatives of dihydroartemisinin. J Med Chem 1998; 41: 4101-8.
95. Grellepois F, Chorki F, Ourevitch M, Charneau S, Grellier P, McIntosh KA, et al. Orally active antimalarials: Hydrolytically stable derivatives of 10-trifluoromethyl anhydrodihydro-artemisinin. J Med Chem 2004; 47: 1423-33
96. Begue, J.-P., Bonnet-delpon, D., Crousse, B., Ourevitch, M., Chorki, F., Grellepois, F., Magueur, G. Novel artemisinine derivatives, and uses thereof for treating malaria. US7417155 (2008).
97. Begue, J.-P., Bonnet-delpon, D., Crousse, B., Ourevitch, M., Chorki, F., Grellepois, F., Magueur, G. Derivatives of artemisinin, and their uses in the treatment of malaria. US20080287433 (2008).
98. Posner GH, Paik IH, Chang W, Borstnik K, Sinishtaj S, Rosenthal AS, et al. Malaria-infected mice are cured by a single dose of novel artemisinin derivatives. J Med Chem 2007; 50: 2516-9.
99. Posner GH, Chang W, Hess L, Woodard L, Sinishtaj S, Usera AR, et al. Malaria-infected mice are cured by oral administration of new artemisinin derivatives. J Med Chem 2008; 51: 1035-42.
100. Woodard LE, Chang W, Chen X, Liu JO, Shapiro TA, Posner GH. Malaria-infected mice live until at least day 30 after a new monomeric trioxane combined with mefloquine are administered together in a single low oral dose. J Med Chem 2009; 52: 7458-62.
101. Posner, G.H., Paik, I., Borstnik, K., Chang, W., Sinishtaj, S., Maio, W.A., D Angelo, J.G., Woodard, L.E., Kalinda, A.S., Usera, A.R., Hess, L.C., Rosenthal, A.S., Oh, S., Baege, A.C. Trioxane dimers having high anticancer and long-lasting antimalarial activities. WO2007067333 (2007), US20090291923 (2009).
102. Ihara, M., Takasu, K., Wataya, Y., Kim, H.-S. Novel trioxa tricyclic compounds having antimalarial activity. EP1262482 (2007).
103. Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: Their growing importance in medicine. Trends Pharmacol Sci 2008; 29: 520-7.
104. Gelb MH. Drug discovery for malaria: A very challenging and timely endeavor. Curr Opin Chem Biol 2007; 11: 440-5.
105. White NJ. Qinghaosu (artemisinin): The price of success. Science 2008; 320: 330-4.
106. Muraleedharan KM, Avery MA. Progress in the development of peroxide-based anti-parasitic agents. Drug Discov Today 2009; 14: 793-803.
107. Singh, C., Malik, H., Puri, S.K. Spiro-1,2,4-trioxanes as antimalarial agents. WO2007077479 (2007).
108. Singh, C., Malik, H., Puri, S.K. Novel spiro-1,2,4-trioxanes. US20070191475 (2007).
109. Singh, C., Prakash, V., Puri, S.K. Novel substituted bis-1, 2, 4- trioxanes and a process for preparation thereof. WO2008099415 (2008).
110. Singh, C., Verma, V.P., Puri, S.K. Novel hydroxy functionalized 1, 2, 4-trioxanes as antimalarial agents and a process for the preparation thereof. WO2009118747 (2009).
111. Singh, C., Singh, A.S., Puri, S.K. Substituted 6-(1-aryl ethyl)-I, 2, 4-trioxanes. WO2008038299 (2008).
112. Muregi FW, Ishih A. Next-generation antimalarial drugs: Hybrid molecules as a new strategy in drug design. Drug Dev Res 2010; 71: 20-32.
113. Meunier, B., Cosledan, F., Pellet, A. Dual molecules containing a peroxide derivative, their synthesis and therapeutic uses. WO2007144487 (2007).
114. Vennerstrom, J.L., Dong, Y., Charman, S.A., Wittlin, S., Chollet, J., Creek, D.J., Wang, X., Sriraghavan, K., Zhou, L., Matile, H., Charman, W.N. Dispiro 1,2,4-trioxolane antimalarials. US20080125411 (2008), WO2009058859 (2009).
115. Vennerstrom, J.L., Dong, Y., Charman, S.A., Wittlin, S., Chollet, J., Wang, X., Sriraghavan, K., Zhou, L., Matile, H., Charman, W.N. Spiro and dispiro 1,2,4-trioxolane antimalarials. WO2009091433 (2009), US20080125441 (2008).
116. Vennerstrom JL, Dong Y, Andersen SL, Ager AL, Jr., Fu H, Miller RE, et al. Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: Alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5. 2]hexadecanes. J Med Chem 2000; 43: 2753-8.
117. McCullough KJ, Wood JK, Bhattacharjee AK, Dong Y, Kyle DE, Milhous WK, et al. Methyl-substituted dispiro-1,2,4,5-tetraoxanes: Correlations of structural studies with antimalarial activity. J Med Chem 2000; 43: 1246-9.
118. Dong Y, Matile H, Chollet J, Kaminsky R, Wood JK. Vennerstrom JL. Synthesis and antimalarial activity of 11 dispiro-1,2,4,5- tetraoxane analogues of WR 148999. 7,8,15,16-Tetraoxa-dispiro [5.2.5.2]hexadecanes substituted at the 1 and 10 positions with unsaturated and polar functional groups. J Med Chem 1999; 42: 1477-80.
119. Terzic N, Opsenica D, Milic D, Tinant B, Smith KS, Milhous WK, et al. Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1). J Med Chem 2007; 50: 5118-27.
120. Amewu, R., O'neill, P.M., Stachulski, A., Ellis, G., Ward, S.A. Dispiro tetraoxane compounds. WO2008038030 (2008).
121. Kim HS, Nagai Y, Ono K, Begum K, Wataya Y, Hamada Y, et al. Synthesis and antimalarial activity of novel medium-sized 1,2,4,5- tetraoxacycloalkanes. J Med Chem 2001; 44: 2357-61.
122. Wataya, Y., Kim, H.-S., Nojima, M. Novel compounds and antimalarials. US7407984 (2008).
123. Goldberg DE. Hemoglobin degradation in Plasmodium-infected red blood cells. Semin Cell Biol 1993; 4: 355-61.
124. Francis SE, Gluzman IY, Oksman A, Banerjee D, Goldberg DE. Characterization of native falcipain, an enzyme involved in Plasmodium falciparum hemoglobin degradation. Mol Biochem Parasitol 1996; 83: 189-200.
125. Eggleson KK, Duffin KL, Goldberg DE. Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J Biol Chem 1999; 274: 32411-7.
126. Rosenthal PJ, McKerrow JH, Aikawa M, Nagasawa H, Leech JH. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J Clin Invest 1988; 82: 1560-6.
127. Klemba M, Gluzman I, Goldberg DE. A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation. J Biol Chem 2004; 279: 43000-7.
128. Rosenthal PJ. Plasmodium falciparum: Effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. Exp Parasitol 1995; 80: 272-81.
129. Rosenthal PJ. Cysteine proteases of malaria parasites. Int J Parasitol 2004; 34: 1489-99.
130. Yeoh S, O'Donnell RA, Koussis K, Dluzewski AR, Ansell KH, Osborne SA, et al. Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes. Cell 2007; 131: 1072-83.
131. Koussis K, Withers-Martinez C, Yeoh S, Child M, Hackett F, Knuepfer E, et al. A multifunctional serine protease primes the malaria parasite for red blood cell invasion. EMBO J 2009; 28: 725-35.
132. Sharma A. Malarial protease inhibitors: Potential new chemotherapeutic agents. Curr Opin Investig Drugs 2007; 8: 642-52.
133. Boss C, Corminboeuf O, Grisostomi C, Weller T. Inhibitors of aspartic proteases - potential antimalarial agents. Exp Opin Ther Patents 2006; 16: 295-317.
134. Herold, P., Mah, R., Tschinke, V., Behnke, D., Jotterand, N., Stojanovic, A. Substituted piperidines as therapeutic compounds. EP2018862 (2009).
135. Herold, P., Mah, R., Tschinke, V., Behnke, D., Marti, C., Jotterand, N., Stutz, S. Substituted piperidines as therapeutic compounds. EP1987834 (2008).
136. Herold, P., Mah, R., Tschinke, V., Stojanovic, A., Behnke, D., Marti, C. Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease. Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease. EP1958634 (2008).
137. Herold, P., Mah, R., Stutz, S., Tschinke, V., Stojanovic, A., Marti, C., Behnke, D., Jotterand, N., Quirmbach, M., Schumacher, C. Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV. EP1764099 (2007), EP1764098 (2007).
138. Herold, P., Stutz, S., Tschinke, V., Stojanovic, A., Marti, C., Quirmbach, M., Schumacher, C. Aminoalcohols as therapeutic compounds. EP1745776 (2007).
139. Herold, P., Stutz, S., Tschinke, V., Stojanovic, A., Marti, C., Quirmbach, M., Schumacher, C. Diaminoalcohols as therapeutic compounds. EP1745778 (2007).
140. Herold, P., Stutz, S., Tschinke, V., Schumacher, C. 5-Amino-4- hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds. EP1867329 (2008).
141. Herold, P., Mah, R., Stutz, S., Tschinke, V., Marti, C., Schumacher, C. Omega-Phenyloctanamides as therapeutic compounds. EP1872780 (2008).
142. Binkert, C., Boss, C., Corminboeuf, O., Grisostomi, C., Meyer, S. Piperazine derivatives as antimalarial agents. WO2007046075 (2007).
143. Aissaoui, H., Boss, C., Corminboeuf, O., Frantz, M.-C. Tetrahydroisoquinolines as antimalarial agents. WO2009141782 (2009).
144. Boss C, Richard-Bildstein S, Weller T, Fischli W, Meyer S, Binkert C. Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr Med Chem 2003; 10: 883-907.
145. Black, C., Mellon, C., Nicoll-griffith, D.A., Oballa, R. Papain family cysteine protease inhibitors for the treatment of parasitic diseases. WO2007012180 (2007).
146. Isabel, E., Mellon, C., Beaulieu, C. Cysteine protease inhibitors for the treatment of parasitic diseases. WO2009067797 (2009).
147. Castellote, A.I., Coteron, L.J.M., Fernandez, V.E.P., Fiandor, R.J.M., Porras, D.F.E. Novel cysteine protease inhibitors. WO2007025774 (2007), WO2007025775 (2007).
148. Coteron, L.J.-M., Fiandor, R.J.M. Kusalakumari, S.S.K. Novel substituted pyrimidines as cysteine protease inhibitors. WO2008052934 (2008).
149. Coteron, L.J.-M., Fernandez, V.E.P. Fiandor, R.J.M. Novel cysteine protease inhibitors. WO2007025776 (2007).
150. Quibell, M., Watts, J.P. Tetrahydrofuro (3, 2-b) pyrrol-3-one derivatives as inhibitors of cysteine proteinases. WO2008007107 (2008).
151. Quibell, M., Watts, J.P., Wang, Y., Patient, L., Heal, J.R. Biologically active compounds. WO2007023281 (2007).
152. Gonzalez, A.F.V., Rodraguez, P.S., Izquierdo, F.J. Cysteine proteases inhibitors. WO2008152178 (2008).
153. Donaldson T, Kim K. Targeting Plasmodium falciparum purine salvage enzymes: A look at structure-based drug development. Infect Disord Drug Targets 2010;10:191-9.
154. de Koning HP, Bridges DJ, Burchmore RJ. Purine and pyrimidine transport in pathogenic protozoa: From biology to therapy. FEMS Microbiol Rev 2005; 29: 987-1020.
155. el Kouni MH. Potential chemotherapeutic targets in the purine metabolism of parasites. Pharmacol Ther 2003; 99: 283-309.
156. Rodenko B, Detz RJ, Pinas VA, Lambertucci C, Brun R, Wanner MJ, et al. Solid phase synthesis and antiprotozoal evaluation of diand trisubstituted 5'-carboxamidoadenosine analogues. Bioorg Med Chem 2006; 14: 1618-29.
157. Loakes, D., Too, K. Antiparasitic compounds and compositions. WO2007135380 (2007).
158. Wiesmann WP, Webster HK, Lambros C, Kelley WN, Daddona PE. Adenosine deaminase in malaria infected erythrocytes: Unique parasite enzyme presents a new therapeutic target. Prog Clin Biol Res 1984; 165: 325-42.
159. Daddona PE, Wiesmann WP, Lambros C, Kelley WN, Webster HK. Human malaria parasite adenosine deaminase. Characterization in host enzyme-deficient erythrocyte culture. J Biol Chem 1984; 259: 1472-5.
160. Wilson DK, Rudolph FB, Quiocho FA. Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. Science 1991; 252: 1278-84.
161. Webster HK, Wiesmann WP, Pavia CS. Adenosine deaminase in malaria infection: Effect of 2'-deoxycoformycin in vivo. Adv Exp Med Biol 1984; 165 Pt A: 225-9.
162. Furneaux, R.H., Tyler, P.C., Evans, G.B., Schramm, V.L., Kim, K., Fröhlich, R. Analogues of coformycin and their use for treating protozoan parasite infections. WO2007097643 (2007).
163. Tyler PC, Taylor EA, Frohlich RF. Schramm VL. Synthesis of 5'- methylthio coformycins: Specific inhibitors for malarial adenosine deaminase. J Am Chem Soc 2007; 129: 6872-9.
164. Yuthavong, Y., Tarnchompoo, B., Kamchonwongpaisan, S. Antimalarial pyrimidine derivatives and methods of making and using them. US7371758 (2008).
165. Tarnchompoo, B., Yuthavong, Y., Vilaivan, T., Chitnumsub, P., Thongpanchang, C., Kamchonwongpaisan, S., Matthews, D., Vivas, L., Yuvaniyama, J., Charman, S., Charman, W., Katiyar, S.B. Antimalarial compounds with flexible side-chains. WO2009048957 (2009).
166. Yuthavong, Y., Vilaivan, T., Kamchonwongpaisan, S., Tarnchompoo, B., Thongpanchang, C., Chitnumsub, P., Yuvaniyama, J., Matthews, D. Charman, W., Charman, S., Vivas, L., Katiyar, S.B. Antimalarial compounds with flexible side-chains. US20090099220 (2009).
167. Krungkrai J. Purification, characterization and localization of mitochondrial dihydroorotate dehydrogenase in Plasmodium falciparum, human malaria parasite. Biochim Biophys Acta 1995; 1243: 351-60.
168. Hurt DE, Widom J, Clardy J. Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. Acta Crystallogr D Biol Crystallogr 2006; 62: 312-23.
169. Phillips, M., Rathod, P.K., Baldwin, J., Gujjar, R. Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity. WO2007149211 (2007).
170. Phillips, M., Rathod, P.K., Gujjar, R., Marwaha, A.S., Charman, S.A. Dihydroorotate dehydrogenase inhibitors with selective antimalarial activity. WO2009082691 (2009).
171. Miller BG, Wolfenden R. Catalytic proficiency: The unusual case of OMP decarboxylase. Annu Rev Biochem 2002; 71: 847-85.
172. Sievers A, Wolfenden R. Equilibrium of formation of the 6- carbanion of UMP, a potential intermediate in the action of OMP decarboxylase. J Am Chem Soc 2002; 124: 13986-7.
173. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419: 498-511.
174. Gero AM, O'Sullivan WJ. Purines and pyrimidines in malarial parasites. Blood Cells 1990; 16: 467-84; discussion 85-98.
175. Kotra, L.P., Pai, E.F., Bello, A.M., Fujihashi, M. ODcase inhibitors for the treatment of malaria. WO2007038859 (2007).
176. Bello AM, Poduch E, Liu Y, Wei L, Crandall I, Wang X, et al. Structure-activity relationships of C6-uridine derivatives targeting plasmodia orotidine monophosphate decarboxylase. J Med Chem 2008; 51: 439-48.
177. Bello AM, Poduch E, Fujihashi M, Amani M, Li Y, Crandall I, et al. A potent, covalent inhibitor of orotidine 5'-monophosphate decarboxylase with antimalarial activity. J Med Chem 2007; 50: 915-21.
178. Yanow SK, Purcell LA, Spithill TW. The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection. Mol Biochem Parasitol 2006; 148: 52-9.
179. Sato A, McNulty L, Cox K, Kim S, Scott A, Daniell K, et al. A novel class of in vivo active anticancer agents: Achiral seco-aminoand seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065. J Med Chem 2005; 48: 3903-18.
180. Lee, M., Spithill, T., Yanow, S., Purcell, L. Compounds for treatment of parasitic infection. WO2008050140 (2008).
181. Vanden, E.J.J., Pietka, A., Huang, T., Mayence. A. Bisbenzimidazoles as antimalarial agents. WO2009043902 (2009).
182. Tuszynski, J.A., Curry, S.H. Compositions and methods for the treatment of malaria. US7265248 (2007).
183. Carballeira NM. New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents. Prog Lipid Res 2008; 47: 50-61.
184. Surolia N. Surolia A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat Med 2001; 7: 167-73.
185. Surolia, A., Surolia, N., Kumar, G., Chhibber, M., Parasuraman, P., Kumar, S., Sharma, S.K., Sharma, S. 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways. US20080051445 (2008)
186. Surolia, A., Sharma, S.K., Surolia, N., Parasuraman, P., Kumar, G. Synergistic composition for modulating activity of substrate analogs for NAD+, NADP+, NADH or NADPH dependent enzymes and process thereof. US20080161247 (2008).
187. Sharma SK, Parasuraman P, Kumar G, Surolia N, Surolia A. Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem 2007; 50: 765-75.
188. Kuntz L, Tritsch D, Grosdemange-Billiard C, Hemmerlin A, Willem A, Bach TJ, et al. Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: Phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase. Biochem J 2005; 386: 127-35.
189. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 1999; 285: 1573-6.
190. Odom AR, Van Voorhis WC. Functional genetic analysis of the Plasmodium falciparum deoxyxylulose 5-phosphate reductoisomerase gene. Mol Biochem Parasitol 170: 108-11.
191. Devreux V, Wiesner J, Jomaa H, Van der Eycken J, Van Calenbergh S. Synthesis and evaluation of alpha,beta-unsaturated alpha-aryl-substituted fosmidomycin analogues as DXR inhibitors. Bioorg Med Chem Lett 2007; 17: 4920-3.
192. Van Calenbergh, S., Haemers, T., Devreux, V., Jomaa, H., Wiesner, J. Organophosphoric derivatives useful as anti-parasitic agents. US7638505 (2009).
193. Doerig C, Abdi A, Bland N, Eschenlauer S, Dorin-Semblat D, Fennell C, et al. Malaria: Targeting parasite and host cell kinomes. Biochim Biophys Acta 1804: 604-12.
194. Canduri F, Perez PC, Caceres RA, de Azevedo WF, Jr. Protein kinases as targets for antiparasitic chemotherapy drugs. Curr Drug Targets 2007; 8: 389-98.
195. Doerig C, Meijer L. Antimalarial drug discovery: Targeting protein kinases. Expert Opin Ther Targets 2007; 11: 279-90.
196. Guan, H., Liang, C., Sun, L., Tang, P.C., Wei, C.C., Vojkovsky, T., Jin, Q., Herrinton, P.M., Mauragis, M.A. 3-(4-Amidopyrrol-2- ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors. US7256189 (2007), US7179910 (2007).
197. Tang, P.C., Sun, C.L., Mcmahon, G., Hirth, K.P., Shawver, L.K. Indolinone combinatorial libraries and related products and methods for the treatment of disease. US7202265 (2007).
198. Winzeler, E., Gray, N.S., Han, D., Cheng, D. Compounds and compositions as kinase inhibitors. WO2008094737 (2008).
199. Chatterjee, A.K., Nagle, A., Wu, T., Gray, N.S. Compounds and compositions useful for the treatment of malaria. WO2009152356 (2009).
200. Andrews KT, Tran TN, Wheatley NC, Fairlie DP. Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr Top Med Chem 2009; 9: 292-308.
201. Kozikowski, A.P., Jung, M., Dritschilo, A. Isoform-selective HDAC inhibitors WO2008019025 (2008).
202. Agbor-Enoh S, Seudieu C, Davidson E, Dritschilo A, Jung M. Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice. Antimicrob Agents Chemother 2009; 53: 1727-34.
203. Becker K, Tilley L, Vennerstrom JL, Roberts D, Rogerson S, Ginsburg H. Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int J Parasitol 2004; 34: 163-89.
204. Muller S. Redox and antioxidant systems of the malaria parasite Plasmodium falciparum. Mol Microbiol 2004; 53: 1291-305.
205. Krauth-Siegel RL, Bauer H, Schirmer RH. Dithiol proteins as guardians of the intracellular redox milieu in parasites: Old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl 2005; 44: 690-715.
206. Davioud-Charvet E, Delarue S, Biot C, Schwobel B, Boehme CC, Mussigbrodt A, et al. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4- anilinoquinoline. J Med Chem 2001; 44: 4268-76.
207. Biot C, Bauer H, Schirmer RH. Davioud-Charvet E. 5-substituted tetrazoles as bioisosteres of carboxylic acids. Bioisosterism and mechanistic studies on glutathione reductase inhibitors as antimalarials. J Med Chem 2004; 47: 5972-83.
208. Bauer H, Fritz-Wolf K, Winzer A, Kuhner S, Little S, Yardley V, et al. A fluoro analogue of the menadione derivative 6-[2'-(3'- methyl)-1',4'-naphthoquinolyl]hexanoic acid is a suicide substrate of glutathione reductase. Crystal structure of the alkylated human enzyme. J Am Chem Soc 2006; 128: 10784-94.
209. Davioud-Charvet, E., Muller, T., Bauer, H., Schirmer, H.R. 1,4- Naphthoquinone derivatives and therapeutic use thereof. WO2009118327 (2009).
210. Gros, P., Min-oo, G, Stevenson MM. Methods and compounds for treatment, prevention and diagnosis of parasitic infection and disease. WO2008092262 (2008).
211. Min-Oo G, Fortin A, Pitari G, Tam M, Stevenson MM, Gros P. Complex genetic control of susceptibility to malaria: Positional cloning of the Char9 locus. J Exp Med 2007; 204: 511-24.
212. Min-Oo G, Ayi K, Bongfen SE, Tam M, Radovanovic I, Gauthier S, et al. Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium. Exp Parasitol 2010; 125: 315-24.
213. Hahn JS. The Hsp90 chaperone machinery: from structure to drug development. BMB Rep 2009; 42: 623-30.
214. Kabakov AE, Kudryavtsev, VA, Gabai, VL. Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med 2010; 88: 241-7.
215. Banumathy G, Singh V, Pavithra SR, Tatu U. Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem 2003; 278: 18336-45.
216. Kumar R, Musiyenko A, Barik S. The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin. Malar J 2003; 2: 30.
217. Shonhai A, Boshoff A, Blatch GL. The structural and functional diversity of Hsp70 proteins from Plasmodium falciparum. Protein Sci 2007; 16: 1803-18.
218. Maier AG, Rug M, O'Neill MT, Brown M, Chakravorty S, Szestak T, et al. Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes. Cell 2008; 134: 48-61.
219. Shonhai A. Plasmodial heat shock proteins: Targets for chemotherapy. FEMS Immunol Med Microbiol 2010; 58: 61-74.
220. Bedin M, Gaben AM, Saucier C, Mester J. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPKindependent cell cycle arrest. Int J Cancer 2004; 109: 643-52.
221. Wenkert, D., Kuhn, L., Scheller, E., Kron, M., Shen, Y. Geldanamycin derivatives and method of use thereof. WO2007098229 (2007).
222. Porter JR, Ge J, Lee J, Normant E, West K. Ansamycin inhibitors of Hsp90: Nature's prototype for anti-chaperone therapy. Curr Top Med Chem 2009; 9: 1386-418.
223. Martin, C., Zhang, M., Gaisser, S., Coates, N. 17-Oxymacbecin derivatives and their use in the treatment of cancer and/or b-cell malignancies. WO2007128827 (2007).
224. Martin, C., Zhang, M., Coates, N., Vousden, W., Moss, S., Gaisser, S. Novel compounds. WO2007128829 (2007).
225. Martin, C.J., Wilkinson, B., Gaisser, S., Zhang, M., Sheridan, R.M., Sheehan, L.S., Lill, R.E., Nur-E-Alam, M., Vousden, W.A., 21-Deoxymacbecin analogues useful as antitumor agents. WO2007074347 (2007).
226. Martin, C. Novel compounds and methods for their production. WO2008056188 (2008).
227. Moss, S., Martin, C., Zhang, M. Novel compounds. WO2008104812 (2008).
228. Nakamoto, K., Matsukura, M., Tanaka, K., Inoue, S., Tsukada, I., Haneda, T., Ueda, N., Abe, S., Sagane, K. Novel antimalarial agent containing heterocyclic compound. US20090227799 (2009).
229. Agon, A.V., Kinnoudo, C. Antimalarial properties of extracts of elaeis guineensis (oil palm) leaves. WO2007129136 (2007).
230. Kaushik, M.P., Thavaselvam, D., Nivsarkar, M., Kumar, S., Sekhar, K., Gogoi, H.K., Koch, D. Bioactive water fraction from Gomphostema niveum. WO2007039916 (2007).
231. Mazier, D., Mahmoudi, N., Farhati, K., Garcia-domenech, R., Galvez, J., Derouin, F., Danis, M. Compounds for preventing and treating Plasmodium infections. WO2009074649 (2009).
232. Gaisser, S., Martin, C., Zhang, M., Wilkinson, B., Sheehan, L., Coates, N., Nur-E-Alam, M., Vousden, W., Gaitatzis, N. Novel compounds and methods for their production. WO2007113266 (2007).
233. Kaushik, M.P., Thavaselvam, D., Nivsarkar, M., Acharya, B.N., Prasanna, S., Sekhar, K. An anti-malarial compound isolated from gomphostema niveum. WO2007039915 (2007).
234. Bukvic, K.M., Kujundzic, N., Ivezic, Z., Alihodzic, S., Hutinec, A., Fajdetic, A. Novel antimalarial 9A-carbamoyl-aminoalkyl and 9a-thiocarbamoyl-aminoalkyl azalides. US20080200404 (2008).
235. Alihodzic, S., Fajdetic, A., Hutinec, A., Ivezic, Z., Kujundzic, N., Rupcic, R. 9A-substituted azalides. WO2007125414 (2007).
236. Alihodzic, S., Fajdetic, A., Hutinec, A., Ivezic, Z., Kujundzic, N., Rupcic, R. 9A-substituted azalides for the treatment of malaria. US20090105301 (2009).
237. Alihodzic, S., Peric, M., Pesic, D. 9A-substituted azalides. WO2009016142 (2009).
238. Alihodzic, S., Peric, M., Pesic, D. 9a-substituted azalides for the treatment of malaria. US20090036388 (2009).
239. Chen, A., Nguyen, Q.V. Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection. WO2008010776 (2008).
240. Hoppe, H.C., Rautenbach, M., Wiehart, U.I.M. Compositions and methods for treating malaria. WO2007023370 (2007).
241. Da Silva, P.A.C., Silva, M.M., De Andrade, V.F., Maia, C.F., Ribeiro, V.P.P., Pohlit, A.M. Derivatives of 4-nerolidylcatechol, pharmaceutical compositions comprising them and process for producing the same. WO2009082795 (2009).
242. Wong, Y.-S., Peuchmaur, M., Marechal, E., Botte, C., Vial, H.J., Saidani, N. Novel polyspirane compounds, application thereof in the treatment of malaria or toxoplasmosis and method for preparing same. WO2009077677 (2009).
243. Deligny, M., Saidani, N., Bonneau, A.-L., Botte, C., Hardre, H., Rousseau, B., Vial, H., Mercier, C., Lopez, R., Marechal, E. Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans. EP1997805 (2008) & WO2008146172 (2008).
244. Bueno, C.J.M., Chicharro, G.J., Lorenzo, G.M., Manzano, C.P.M. Novel heterocyclic compounds. WO2007138048 (2007).
245. Onori E, Majori G. Recent acquisitions on chemotherapy and chemoprophylaxis of malaria. Ann Ist Super Sanita 1989; 25: 659-73.
246. Rieckmann KH, Yeo AE, Edstein MD. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans R Soc Trop Med Hyg 1996; 90: 568-71.
247. Canfield CJ, Milhous WK, Ager AL, Rossan RN, Sweeney TR, Lewis NJ, et al. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg 1993; 49: 121-6.
248. Canfield, C., Jacobus, D.P., Levis, N.J. N,N'-Substituted imidodicarbonimidic diamides derived from hydroxylamines. US5322858 (1994).
249. Jacobus, D.P., Schiehser, G.A., Shieh, H.-M., Jensen, N.P., Terpinski, J. Biguanide and dihydrotriazine derivatives. US7256218 (2007).
250. Pitzer, K.K., Scovill, J.P., Kyle, D.E., Gerena, L. Indolo 2,1- b]quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith. EP1032574 (2007).
251. Gilles, G., Gersanda, L., Lallemand, E., Renia, L. Aza heterocyclics for the treatment of malaria or aids. WO2007074171 (2007).
252. Gilles, G., Gersande, L., Lallemand, E., Renia, L. Compositions and methods for the treatment and prevention of disease. WO2007074170 (2007).
253. Simpson JA, Jamsen KM, Price RN, White NJ, Lindegardh N, Tarning J, et al. Towards optimal design of anti-malarial pharmacokinetic studies. Malar J 2009; 8: 189-95
254. Touitou E, Waknine JH, Godin B, Golenser J. Int J Parasitol 2006; 36: 1493-8.
255. Fang, H., Gao, H., Zhou, Y., Li, Y. Dihydroartemisinin jelly glue patch and preparation method thereof. CN101467993 (2009).
256. Vacca, R.D. Transdermal, alcohol-free, pharmaceutical compositions. WO2009036311 (2009).
257. Wang, Q., Li, Z., Zhao, W., Zeng, Y., Sun, Y., Ai, P. Arteannuin transdermal patch substrate, preparation method and arteannuin transdermal patch thereof. CN101433516 (2009).
258. Ye, Z., Wang, N., Zhang, Z. Transdermal preparations comprising artemisinin and/or its derivatives. WO2008037176 (2008).
259. Schuster, J.A., Cipolla, D.C., Farr, S. Processes for taste-masking of inhaled formulations. US20080138397 (2008).
260. Liyan, Q., Na, J. Chloroquine liposomes freeze-dried powder injection and preparation method thereof. CN101283987 (2008).
261. Duncalf, D.J., Essa, A.H., Foster, A.J., Long, J., Rannard, S.P., Wang, D. Improvements relating to anti-parasitic compositions. WO2008006713 (2008).
262. Turos, E., Cormier, R., Kyle, D.E. Polyacrylate nanoparticle drug delivery. WO2009055650 (2009).
263. Costa FTM, Justo GZ, Caballero NED, Nogueira PA, Lopes SCP. Use of violacein in free form or encapsulated in antimalarial polymeric systems. BR2005006399A (2007).
264. Godha, P., Bansal, Y.K., Sengupta, S. A process for preparation of stable sustained release antimalarial formulation. Kadam S. IN2007MUM01340A (2009).
265. Godha, P., Bansal, Y.K., Sengupta, S., Singh, N. Delayed release anti-malarial composition. WO2007036947 (2007).
266. Motiwale, V.G. Stable antimalarial formulations. IN2007MU00467A (2008).
267. Iderne, M. Spheroides multicouches a action antipaludique dont l'une des couches contient de l'artesunate. FR2914860 (2008).
268. Benakis, A. Antimalarial composition in geometrical solid tablet form obtained by the compression of a medicine powder and excipients, useful to treat malaria, comprises three separate layers. CH696229A5 (2007)
269. Jiang, H., Sun, S., Liu, F., Luo, C., Cao, Y. Composite three-layer tablet of amodiaquine hydrochloride and artesunate. CN101129372 (2008).
270. Yu, Y. Double hydrogen arteannuic plain guagui slice and preparing method thereof. CN101199489 (2008).
271. Li, G., Song, J. Malaria-resisting arteannuin naphthoquine compound composition. CN101116665 (2008).
272. Jiang, H., Sun, S., Liu, F., Luo, C., Cao, Y. Three-segment pin compound of hydrochloric acid amodiaquine and dihydroartemisinin. CN101108160 (2008).
273. Fu, B., Huang, Z., Luo, G. Malaria assistance bi-hydrogen arteannuin suppository. CN101361706 (2009).
274. Wen, X. Artemether self-emulified capsule and its preparing method. CN1935126 (2007).
275. Kong, L., Wei, J. Preparation for artesunate liquid-filling capsule for treating malaria CN101317838 (2008).
276. Kong, L., Wei, J. Preparation for benflumetol dripping pill for treating malaria. CN101317833 (2008).
277. Kong, L., Wei, J. Preparation method of artemether drop pills for treating malaria CN101310720 (2008).
278. Ma, Y., Hu, H., Chen, T., Lu, T., Chen, Y. Mefloquine fat emulsion composition and method for preparing the same. CN101474152 (2009).
279. Ellis, W.Y., Lim, P., Maniar, M. Methods for the formulation and manufacture of artesunic acid for injection. WO2007146288 (2007).
280. Chen, P., Couch, R. Crystalline form of an antimalarial compound. WO2009068623 (2009).
281. Sun, T., Lorimer, K., Meyer, K.W., Nielsen, K.R., Watson, S. Quinine sulfate polymorphs, processes of preparing, compositions and uses thereof. US2009163540 (2009).
282. Omara-Opyene AL, Moura PA, Sulsona CR, Bonilla JA, Yowell CA, Fujioka H, et al. Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J Biol Chem 2004; 279: 54088-96.